Inhibace

Cilazapril, the active ingredient in Inhibace, is an angiotensin-converting enzyme (ACE) inhibitor presented as an oral tablet for oral use. It is employed to lower elevated blood pressure and to improve outcomes in patients with heart failure, acting by relaxing blood vessels and reducing cardiac workload.

GNH USA supplies Inhibace as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Our distribution network ensures timely delivery and reliable product integrity.

Cilazapril is an ACE inhibitor used in the management of cardiovascular conditions.

Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke and myocardial infarction. Heart failure: improves symptoms, decreases hospitalisations and mortality by reducing afterload. Diabetic nephropathy: controls blood pressure to slow progression of kidney disease in patients with diabetes.

Cilazapril may cause a range of adverse reactions, which are generally categorized by frequency.

Common Side Effects: - Cough: dry, persistent cough. - Dizziness: especially on standing. - Headache. - Fatigue. - Hyperkalaemia: mild increase in serum potassium. - Hypotension: transient low blood pressure after first dose.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, potentially compromising airway. - Severe neutropenia: marked reduction in white blood cells. - Acute renal failure: sudden decline in kidney function. - Hepatotoxicity: elevated liver enzymes or hepatitis.

When prescribing or dispensing Cilazapril, consider the following precautions to ensure safe use.

Pregnancy: contraindicated in second and third trimesters due to fetal risk. Renal impairment: dose adjustment may be required and kidney function should be monitored. Hyperkalaemia: avoid concomitant potassium‑sparing agents and monitor serum potassium levels. Hypotension: assess volume status before initiation, especially in patients on diuretics. Drug‑specific monitoring: periodic assessment of blood pressure, renal function and electrolytes is recommended. Store at ambient temperature: keep below 25°C, protect from moisture and light in the original packaging.

Cilazapril can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren: combined use in diabetes or renal impairment may increase adverse‑effect risk. - Potassium‑sparing diuretics or potassium supplements: may cause dangerous hyperkalaemia. - High‑dose NSAIDs (e.g., ibuprofen): can blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance hypotensive effect; monitor blood pressure. - Lithium: ACE inhibition can raise lithium levels; watch for toxicity. - Antidiabetic agents (insulin, sulfonylureas): may increase hypoglycaemia; adjust dose as needed. - Rifampin: may reduce Cilazapril plasma concentrations; monitor therapeutic response.